Breastfeeding After Methotrexate Treatment for Ectopic Pregnancy

Rationale for Waiting Period

Breastfeeding should be discontinued until at least 3 months after the last dose of methotrexate for ectopic pregnancy treatment, as methotrexate is a teratogen that is excreted into breast milk, according to the British Association of Dermatologists' guidelines 1, 2
Methotrexate is classified as pregnancy category X, indicating significant risk to developing fetuses, as stated by the American Academy of Dermatology 3, 4

Methotrexate is excreted into breast milk, potentially exposing the nursing infant to its effects, which can interfere with rapidly dividing cells, according to the British Journal of Dermatology 1
The drug poses a risk of accumulation in infant tissues and immunosuppression in the nursing infant, as reported by the American Academy of Dermatology 3, 5

Discontinue breastfeeding immediately upon methotrexate administration and advise on alternative feeding methods, as recommended by the British Association of Dermatologists 1, 2, 4
Wait at least 3 months after the last methotrexate dose before resuming breastfeeding, which aligns with recommendations for conception after methotrexate treatment, according to the British Journal of Dermatology and the American Academy of Dermatology 1, 2, 3

Explain that the waiting period is necessary to ensure complete clearance of the medication from maternal tissues, and discuss alternative feeding options during the waiting period, as advised by the American Academy of Dermatology and the British Association of Dermatologists 1, 3
Emphasize that premature resumption of breastfeeding could potentially expose the infant to methotrexate, and reassure that after the 3-month waiting period, breastfeeding can likely be safely resumed, according to the British Journal of Dermatology and the American Academy of Dermatology 1, 4